LAG525 Solid and Hematologic Malignancies trial completed, page-39

At SITC

	#	Type	Title	Authors	Category	Keywords
1	387	Poster Presentation	A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies	Chia-Chi Lin, MD, PhD; Elena Garralda, MD; Patrick Schöffski; David S. Hong, MD; Lillian Siu, MD; Miguel Martin, MD; Michela Maur, MD; Rina Hui, MD; Ross Soo, MD; Joanne Chiu, MD; Tian Zhang, MD; Brigette Ma, MD; Chrisann Kyi, MD; Daniel Tan, MBBS, MRCP; Philippe Cassier, MD; John Sarantopoulos, MD; Andrew Weickhardt, MBBS, FRACP, DMedSc; Rich Carvajal, MD; Jennifer Spratlin, MD; Taito Esaki, MD; Fréderic Rolland; Wallace Akerley, MD; Barbara Deschler-Baier; Catherine A. Sabatos-Peyton, PhD; Niladri Roy Chowdhury, PhD; Daniel Gusenleitner, PhD; Eunice Kwak, PhD; Vasileios Askoxylakis, PhD; Filippo De Braud;	In-Progress Clinical Trials	Antibody; Checkpoint blockade; Clinical trial; Coinhibition; Solid tumors